ANI Pharmaceuticals, Inc.

ANIP Healthcare Drug Manufacturers Specialty & Generic

ANI Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $883.4 million, up 43.8% from fiscal 2024. In the quarter to June 2026, revenue grew 25.9%, EPS grew 194.6%, free cash flow fell 22.2% and total debt fell 1.78%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

72.08 0.20 −0.28%
Market cap
$1.7B
P/E
14.9×
Fwd P/E
14.5×
Dividend yield
—
F-score
7/9
Altman Z
2.30
Beneish M
−2.62
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
17.14 18.71 22.55 53.57

+8 more quarters

P/S ratio
1.79 1.74 1.79 2.22
P/FCF ratio
10.46 8.80 10.49 13.59
P/Operating CF
30.91 27.55 52.13 41.74
P/B ratio
2.93 2.86 2.93 3.64
Price to Tangible BV
20.64 49.24 0.00 0.00
EV/Sales
2.03 2.05 2.16 2.65
EV/EBITDA
8.41 8.89 9.41 12.59
EV/Operating CF
10.48 9.09 10.29 12.81
EV/FCF
11.86 10.37 12.63 16.17
Quick Ratio
2.29 2.43 2.07 1.94
Current Ratio
2.91 3.12 2.71 2.58
Net Debt/EBITDA
3.90 4.81 5.62 5.92
Debt/Assets
40.86% 43.16% 42.84% 44.05%
Debt/Equity
1.02 1.09 1.14 1.23
Asset Turnover
0.69 0.68 0.65 0.61
Operating CF/Net income
2.29 1.98 1.10 1.68
Capex/Depreciation
(0.16) (0.54) (0.06) (0.27)
Interest Coverage
11.13 10.32 7.88 7.67
Research and Development Expense of Revenue
5.54% 4.46% 4.96% 5.40%
Selling, General and Administrative Expense of Revenue
34.45% 31.02% 33.51% 33.65%
Intangible Assets out of Total Assets
0.34 0.37 0.38 0.40
Share Based Compensation of Revenue
4.29% 4.29% 3.95% 4.25%
Graham Net Nets
(0.04) (0.07) (0.09) (0.11)
Graham Number
55.39 49.86 46.08 31.14
Earnings Yield
5.83% 5.34% 4.43% 1.87%
Free Cash Flow Yield
9.56% 11.37% 9.53% 7.36%
Revenue per Share
12.57 11.35 12.32 11.35
Operating CF per Share
2.68 2.79 1.51 2.19
Capex per Share
(0.14) (0.54) (0.07) (0.31)
Free Cash Flow per Share
2.53 2.25 1.44 1.89
Cash per Share
17.77 15.59 14.70 13.53
Shareholders Equity per Share
28.23 26.89 26.96 25.20
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
28.23 26.89 26.96 25.20
Free Cash Flow
53.62 47.05 28.96 37.89
Working Capital
541.78 507.57 475.01 427.85
Capital Expenditures
(3.05) (11.32) (1.40) (6.16)
Net Current Asset Value
(71.47) (112.59) (146.54) (203.93)
EV/EBIT
13.21 15.32 17.15 30.41
Capex to Sales
0.01 0.05 0.01 0.03
Price to Operating Income
11.65 12.99 14.25 25.56
Other line items
Average Receivables
250.06 237.88 251.40 224.49
Average Payables
64.20 61.38 54.12 65.34
Average Inventory
140.73 140.44 139.92 147.26
Average Assets
1,418.56 1,357.20 1,362.42 1,347.76
Average Common Equity
516.98 490.46 472.20 455.88

Fold the line items

Columns are period end dates